Mechanistic Insights Into Celastrol’s Anti‐Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation
Mediators of Inflammation · 2025-01 · 2025 (1)
DOI: 10.1155/mi/5676471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 08.09.2025. Verfasst von Xiaotian Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China. Hauptthemen laut MEDLINE: Pentacyclic Triterpenes, Osteoarthritis, Sirtuin 2, Pyroptosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic inflammation and cell apoptosis are hallmark characteristics of osteoarthritis (OA), necessitating the development of novel therapeutic strategies. Celastrol (CSL) has emerged as a promising agent for OA treatment due to its anti‐inflammatory properties, but the specific mechanism of action remains unclear.
Methods
This study utilized network pharmacology and in vivo experiments to elucidate how CSL modulates the SIRT2‐NLRP3 axis in OA. Chondrocytes were treated with CSL to evaluate changes in SIRT2 expression and NLRP3 acetylation levels. OA rats were administered CSL to assess its therapeutic effects.
Results
Using network pharmacology and bioinformatics, SIRT2 and NLRP3 were identified as the primary therapeutic targets of CSL for OA. In vitro experiments demonstrated that CSL significantly reduced the levels of inflammatory markers and pyroptosis‐related proteins, such as GSDMD‐N, in TC28a cells and primary rat chondrocytes (RCs) induced by lipopolysaccharide (LPS) and nigericin (Nig). CSL upregulated SIRT2 expression, decreased NLRP3 acetylation, and promoted anti‐inflammatory cytokine expression (IL‐4 and IL‐10), thereby, reducing inflammation and pyroptosis in chondrocytes. Notably, SIRT2 knockdown reversed CSL’s anti‐inflammatory and anti‐pyroptosis effects. In vivo, CSL significantly alleviated OA symptoms in rats by modulating the SIRT2/NLRP3 pathway.
Conclusion
CSL exerts its anti‐inflammatory effects in OA by targeting the SIRT2‐NLRP3 axis to inhibit chondrocyte pyroptosis. These findings underscore the potential of CSL as a therapeutic agent for mitigating OA progression and offer new insights into its molecular mode of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
- Anhui Province Key Laboratory of Tissue Transplantation, Bengbu Medical University, Bengbu 233004, China.
- School of Pharmacy, Bengbu Medical University, Bengbu 233030, China.
ORCID-Profile: Xiaotian Chen, Yining Song, Fan Zhang, Fangyan Hu, Zhenfei Ding, Jianzhong Guan
Zitieren
APA
Chen, X., Song, Y., Zhang, F., Hu, F., Ding, Z., & Guan, J. (2025). Mechanistic Insights Into Celastrol’s Anti‐Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation. Mediators of Inflammation, 2025(1). https://doi.org/10.1155/mi/5676471
Vancouver
Chen X, Song Y, Zhang F, Hu F, Ding Z, Guan J. Mechanistic Insights Into Celastrol’s Anti‐Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation. Mediators of Inflammation. 2025;2025(1). doi:10.1155/mi/5676471
BibTeX
@article{Chen2025,
author = {Chen, Xiaotian and Song, Yining and Zhang, Fan and Hu, Fangyan and Ding, Zhenfei and Guan, Jianzhong},
title = {Mechanistic Insights Into Celastrol’s Anti‐Pyroptosis Effects in Osteoarthritis via SIRT2 Upregulation},
journal = {Mediators of Inflammation},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/mi/5676471}
}
EUVIMED